A drug that only enters
the damaged brain
The analysis identified a novel delivery concept: an oral compound that intentionally fails to cross a healthy blood-brain barrier — entering exclusively through the structurally compromised BBB in HD-affected striatal tissue.
The PHYSIM Platform: A deterministic computational physics platform. Governed by strict mathematical laws, the system maps the entire human genome across every known disease to compute biological certainty, not generative probability. AI serves only as our translator — the core analysis is reproducible, auditable, and deterministic.
This does not replace the laboratory — it de-risks before you get there. Instead of screening thousands of candidates blindly, the system narrows the search space to a focused set of computationally validated targets worth testing. Each finding on this page is a possible new discovery — a possible path toward helping patients — that deserves rigorous experimental validation.
The disease itself becomes the delivery gateway
Traditional CNS drugs optimize for maximum BBB penetration (high logBB). This saturates all brain tissue equally — healthy and diseased — causing the neuro/psychiatric side effects that plague every HD drug program.
This candidate takes the opposite approach: it is deliberately designed to fail at crossing a healthy BBB.
It enters the brain only where the BBB is already compromised by HD-driven striatal inflammation. Healthy cortex is physically excluded.
The result: A compound that concentrates in exactly the tissue that needs it, while leaving healthy brain tissue untouched. Massive safety margins on psych/neuro side effects.
Oral PAI-1 Inhibitor — CNS Fibrinolytic Axis
Targets toxic fibrin clearance in the striatum. The compound profile was computationally predicted through the disease cascade analysis.
Every HD drug fails the same way
CNS drugs for Huntington's are optimized to cross the BBB as efficiently as possible. But maximum BBB penetration means the compound floods all brain tissue — including healthy regions that don't need it. This is why every HD drug program produces dose-limiting psychiatric and neurological toxicity.
The Math Behind the BBB Gating
To verify the therapeutic entry pathway, we ran a multi-layered structural intersection between the compromised HD blood-brain barrier and the PAI-1 inhibitor. A score below 0.10 indicates structural parity beyond random noise.
"Help for today. Hope for tomorrow."
— Huntington's Disease Society of America (HDSA), mission statement
Commission a Computational Disease Analysis
We produce pre-clinical CDA reports that map your disease of interest across the full human genome — identifying novel pathways, repurposable compounds, and structural drug targets before you enter the lab. Tell us what you’re working on.
Start a Conversation →